Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Digital family program aims to curb diabetes and hypertension across europe

NCT ID NCT05648383

Prevention Sponsor: Harokopio University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested a 24-month program that combined face-to-face counseling with digital tools to help families prevent and manage type 2 diabetes and high blood pressure. Over 1,200 adults and their children from Albania, Bulgaria, Greece, and Spain took part. The program encouraged healthier lifestyles as a family, using mobile apps for self-monitoring and support. Researchers measured changes in blood sugar and blood pressure to see if the program worked better than standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mHealth self-management intervention (behavioral)
What this could lead to
If successful, this could provide a scalable, family-centered digital approach to prevent and manage type 2 diabetes and hypertension, reducing the burden of these chronic conditions.
What could go wrong
This is a completed trial, but results are not yet widely published. The intervention is complex and may not be easily adopted in all communities. Long-term benefits beyond 24 months are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,215 people

The number who actually took part.

Started

Oct 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * People who have their permanent residence within the prefecture/region of the relevant facility participating in the clinical study. * People having children at primary and/ or secondary education. * People who are physically and mentally able to provide their informed consent to participate. * People with a FINDRISC ≥10 * People with a fasting plasma glucose (FPG) ≥ 100 mg/dL and /or glycated hemoglobin (HbA1c) ≥ 5.7% Exclusion Criteria: * People suffering from a health condition where adherence to the intervention will be contraindicated or improbable. * People unable to express a free and informed consent for medical and/or psychological conditions, mental incapacity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus hypertensive disorder Obesity obesity disorder Overweight prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Obesity & overweight Prediabetes Type 2 diabetes

Contacts and locations

Locations

  • Harokopio University

    Athens, Attica, 17676, Greece

  • Medical University of Varna

    Varna, Varna, 9002, Bulgaria

  • Universidad de Zaragoza

    Zaragoza, Zaragoza, 50009, Spain

  • Universiteti i Mjekësisë

    Tirana, Rruga E Dibrës, AL1005, Albania

More trials for these conditions

Other studies related to the condition(s) this trial covers.